Differential Prognostic Impact of Potent P2Y₁₂ Inhibitors in Patients With Acute Myocardial Infarction by Bleeding...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Limited comparative data exists for potent P2Y₁₂ inhibitors versus clopidogrel in acute myocardial infarction (AMI) patients stratified by bleeding risk.
• This study addresses the differential prognostic impact of potent P2Y₁₂ inhibitors based on bleeding risk in AMI.

Purpose of the Study:

• To evaluate the comparative efficacy and safety of potent P2Y₁₂ inhibitors against clopidogrel in AMI patients.
• To assess the impact of bleeding risk stratification on treatment outcomes.

Main Methods:

• Utilized a nationwide pooled registry of the Korea Acute Myocardial Infarction Registry.
• Propensity score-matched 1,144 high bleeding risk (HBR) and 6,181 non-HBR pairs comparing potent P2Y₁₂ inhibitors to clopidogrel.
• Primary outcomes included 3-year major adverse cardiac and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding.

Main Results:

• In HBR patients, MACCE risk was similar between potent P2Y₁₂ inhibitors and clopidogrel (aHR, 1.00; p=0.996).
• Non-HBR patients showed significantly lower MACCE risk with potent P2Y₁₂ inhibitors (aHR, 0.78; p<0.004).
• Potent P2Y₁₂ inhibitors increased bleeding risk in both HBR (aHR, 1.67; p=0.004) and non-HBR patients (aHR, 1.66; p<0.001).

Conclusions:

• Potent P2Y₁₂ inhibitors demonstrated reduced MACCE risk exclusively in non-HBR AMI patients.
• An increased risk of bleeding was observed with potent P2Y₁₂ inhibitors compared to clopidogrel, irrespective of bleeding risk.
• Treatment decisions should consider individual bleeding risk when selecting P2Y₁₂ inhibitors.